Pharming Announces Positive Results from Randomized Controlled Trial with RUCONEST® for HAE Prophylaxis

LEIDEN, The Netherlands, July 18, 2016 /PRNewswire/ --

RUCONEST(R) showed clinically and statistically significant reduction in attack
frequency both in twice weekly and once- weekly dosing 
Pharming Group N.V. ("Pharming" or "the Company") today announced positive results from a Phase 2 clinical study of RUCONEST(R) (recombinant C1 esterase inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).  In the study, RUCONEST(R) showed a clinically relevant and statistically significant reduction in attack frequency for both the twice-weekly and once-weekly treatment regimens as compared with placebo.
Thirty-two HAE patients deficient in C1 esterase inhibitor and with a history of at least four attacks per month were enrolled in the randomized, double-blind, placebo-controlled study. The patients received RUCONEST(R) once and twice weekly and placebo in each of three four-week treatment periods in a cross-over design. The primary efficacy endpoint was the number of HAE attacks per 28 day treatment period and the secondary endpoint was clinical response, defined as a greater than or equal to 50% reduction in the number of attacks from treatment with placebo to treatment with RUCONEST (R).
In the intent-to-treat analysis (ITT), the study found a statistically significant difference in the mean number of HAE attacks that patients experienced during treatment with both the twice-weekly (p-value  

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234